Maxi Investments CY Ltd Purchases 44,600 Shares of 10x Genomics $TXG

Maxi Investments CY Ltd raised its position in 10x Genomics (NASDAQ:TXG) by 270.3% during the third quarter, Holdings Channel reports. The institutional investor owned 61,100 shares of the company’s stock after buying an additional 44,600 shares during the quarter. 10x Genomics makes up about 1.0% of Maxi Investments CY Ltd’s investment portfolio, making the stock its 24th biggest holding. Maxi Investments CY Ltd’s holdings in 10x Genomics were worth $5,521,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quantinno Capital Management LP lifted its stake in shares of 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after acquiring an additional 744,558 shares during the period. Dimensional Fund Advisors LP increased its position in 10x Genomics by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after purchasing an additional 525,369 shares during the period. Quantedge Capital Pte Ltd increased its position in 10x Genomics by 104.2% in the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after purchasing an additional 212,600 shares during the period. Hsbc Holdings PLC acquired a new position in 10x Genomics during the 1st quarter valued at about $5,945,000. Finally, Swiss National Bank lifted its position in 10x Genomics by 2.2% during the 1st quarter. Swiss National Bank now owns 207,400 shares of the company’s stock valued at $4,403,000 after purchasing an additional 4,400 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Stock Up 2.0%

Shares of 10x Genomics stock opened at $72.96 on Tuesday. The business has a fifty day simple moving average of $72.70 and a 200 day simple moving average of $39.39. The stock has a market cap of $9.51 billion, a PE ratio of -123.66 and a beta of 1.99. 10x Genomics has a 12 month low of $12.34 and a 12 month high of $102.81.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. The firm had revenue of $151.04 million for the quarter, compared to analyst estimates of $146.67 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The company’s quarterly revenue was down 12.7% on a year-over-year basis. Analysts expect that 10x Genomics will post -0.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. UBS Group initiated coverage on shares of 10x Genomics in a research report on Wednesday, September 9th. They set a “neutral” rating and a $68.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Royal Bank Of Canada assumed coverage on shares of 10x Genomics in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 price objective on the stock. Stephens cut shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research note on Friday. Finally, Leerink Partners raised their price objective on shares of 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research note on Tuesday, September 29th. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $68.00.

Insider Activity at 10x Genomics

In other news, insider Benjamin Hindson sold 13,818 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $63.02, for a total value of $870,810.36. Following the completion of the sale, the insider directly owned 488,182 shares of the company’s stock, valued at $30,765,229.64. This represents a 2.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Shehnaaz Suliman sold 5,723 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the sale, the director owned 23,792 shares in the company, valued at $1,931,672.48. This represents a 19.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 179,333 shares of company stock worth $11,810,070. 8.84% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.